PT-141 (Bremelanotide) Research Guide: Structure, Mechanism, Preclinical Findings and Handling

For laboratory research use only; not for human consumption. This guide brings together what is known about PT-141 as a laboratory peptide: its melanocortin lineage, ring chemistry, receptor pharmacology, the preclinical systems in which it is characterized, and how to handle and verify a research batch. It is research education rather than usage guidance. Research-grade material is on the PT-141 product page, and a shorter primer is available in what is PT-141.

What PT-141 is

PT-141, also called bremelanotide, is a cyclic peptide of seven residues that activates melanocortin receptors. The melanocortin system comprises five G-protein-coupled receptors (MC1R to MC5R) and their endogenous ligands: alpha-, beta- and gamma-melanocyte-stimulating hormones and ACTH, all cleaved from the precursor proopiomelanocortin. Different receptors dominate in different tissues. MC1R is associated with pigmentation signaling in skin, MC2R is the ACTH receptor of the adrenal cortex, MC3R and MC4R are prominent in the central nervous system, and MC5R is found in exocrine tissues. PT-141 is studied chiefly for its central MC4R activity, which makes it a useful tool for separating that branch of the family from the broader pigmentation-linked activity of its parent, melanotan-II.

It is important to keep names precise. PT-141 and bremelanotide are the same defined compound; melanotan-II is a related but different peptide with its own research record, summarized in melanotan-II research overview. Findings from one should not be transferred to the other without a direct comparison.

Discovery and history

The lineage begins with alpha-MSH, the tridecapeptide whose short core sequence His-Phe-Arg-Trp is the signature recognition motif of the melanocortin receptors. Native alpha-MSH is quickly degraded, so medicinal chemists in the 1970s and 1980s, notably Victor Hruby, Mac Hadley and colleagues at the University of Arizona, designed analogs with greater potency and stability. The linear analog NDP-MSH (with norleucine at position 4 and D-phenylalanine at position 7) was described by Sawyer and colleagues in 1980. Cyclization using a lactam bridge between Asp and Lys side chains then produced melanotan-II, reported by Al-Obeidi and colleagues in 1989 as a superpotent cyclic alpha-melanotropin.

PT-141 emerged from that program as a close structural relative. It is the same cyclic core as melanotan-II but with a free C-terminal acid instead of the C-terminal amide; formally this is a deamidated analog, and it was characterized in the context of studies of the metabolism of melanotan-II. That small change shifted its pharmacological emphasis. Whereas melanotan-II strongly engages MC1R, giving it a prominent pigmentation signal in models, PT-141 drew attention for its central MC4R-linked activity and was given the designation PT-141 as it was pursued as a distinct entity. Reviews by Hadley and Dorr and by Molinoff and colleagues trace this progression.

The historical lesson is that PT-141 was found through iterative analog and metabolite characterization, not isolated from a natural source. Relative receptor preference depends on assay system, so it is more accurate to describe a focused MC4R emphasis than absolute exclusivity. A shorter timeline is in PT-141 discovery and history.

Chemical structure and synthesis

The cyclic melanocortin core

PT-141 contains the His-D-Phe-Arg-Trp pharmacophore flanked by Asp and Lys, whose side chains are joined by an amide (lactam) bond. Ring closure restricts the conformational freedom of the backbone and favors a turn that presents the pharmacophore to the receptor. Constraining a peptide in this way is a standard strategy for improving enzymatic stability and defining a single preferred shape; it can also sharpen subtype selectivity. The N-terminal norleucine replaces methionine in the native hormone, avoiding oxidation-prone sulfur, and the D-phenylalanine increases resistance to proteolysis and stabilizes the bioactive turn.

Synthesis and cyclization

Research material is made by solid-phase peptide synthesis, assembling the chain on a resin with orthogonally protected Asp and Lys side chains. After selective deprotection, on-resin cyclization forms the lactam bridge, and the peptide is cleaved, purified by preparative reverse-phase HPLC and lyophilized (see what is lyophilization). Choosing a resin linker that releases a free acid is what yields the PT-141 terminus; an amide-forming linker would give the melanotan-II terminus instead.

Impurities to expect

Cyclization is the delicate step. Incomplete ring closure leaves a linear precursor, which has a mass 18 Da higher than the cyclic product. Intermolecular coupling can produce dimers, deletion sequences arise from incomplete coupling, and D/L epimerization at sensitive residues yields diastereomers with nearly identical mass. This is why a nominal mass match alone cannot prove identity: chromatographic behavior and the known synthesis route must be read together. Chromatographic purification separates these species, and the expected mass change on cyclization supports formation of the designed ring. Details are in PT-141 chemical structure and synthesis, and the complementary roles of the two analytical methods are explained in HPLC vs mass spectrometry.

Mechanism of action

Receptor engagement and signaling

PT-141 is an agonist at melanocortin receptors, with the greatest research attention on MC4R. MC4R couples to Gs, activating adenylyl cyclase and raising intracellular cAMP; downstream, protein kinase A and CREB-dependent transcription can follow. MC4R is expressed widely in the hypothalamus and other brain regions, which is why the receptor is treated as a central signaling node rather than a peripheral one. Under some conditions melanocortin receptors also signal through other routes, including beta-arrestin recruitment and ERK pathways, so a single cAMP readout does not describe the entire response.

Why selectivity must be measured, not assumed

Because the receptors form a family distributed across tissues, observed effects in a model depend on which subtypes it expresses. A cAMP signal alone cannot reveal which receptor produced it. Rigorous work therefore uses receptor-defined cell lines expressing a single subtype, binding competition experiments, and genetic or pharmacological controls to test whether MC4R is required. Binding affinity and signaling efficacy are separate quantities: a ligand can bind tightly yet give a different maximal response than another agonist, and assay amplification can make modest receptor activation look large downstream. Reporting both gives a clearer account.

Time and compartment as variables

Receptor activation, cAMP accumulation, receptor internalization and transcriptional adaptation occur on different time scales, so sampling a single time point can blur distinct stages. Time-resolved assays separate immediate G-protein coupling from later adaptation, and matched viability controls reduce the chance that nonspecific cellular stress is mistaken for receptor-mediated signaling. Concentrations in in-vitro work are set by assay design and describe controlled model behavior only. The mechanism is summarized separately in PT-141 mechanism of action, and a related alpha-MSH-derived tripeptide is compared in KPV vs alpha-MSH.

Preclinical research findings

Preclinical characterization of PT-141 has followed the standard ladder from receptor-level assays to intact animals. The recurring experimental question is how the free-acid terminus changes subtype potency and efficacy relative to melanotan-II.

What the animal literature shows

In rodents, Pfaus and colleagues reported in 2004 that a melanocortin receptor agonist selectively facilitated appetitive behaviors in female rats, an effect that depended on central melanocortin signaling and could be attenuated by receptor antagonism. That work is typically cited as demonstration of a centrally mediated response to the compound in an intact animal. Earlier and parallel work with the parent compound melanotan-II, reviewed by Hadley and Dorr, mapped the range of melanocortin-linked endpoints, including pigmentation and feeding-related behavior, which is why comparison of the two molecules remains central to the literature.

How to read these findings

Results from cells and animals describe pathway engagement under defined laboratory conditions and are not transferable claims about any other setting. Identity and purity of the test material are essential variables, since closely related melanocortin analogs can behave very differently after small structural changes: a batch containing the linear precursor or an epimer could produce a different pharmacological profile from the intended cyclic form. Researchers designing assays should document lot-level analytical data and storage history. More detail is in PT-141 preclinical research and the broader PT-141 research overview.

Handling, reconstitution and storage

PT-141 is supplied as a lyophilized powder, the most stable physical form. The cyclic backbone limits exposure to exopeptidases, which makes it generally more stable than a linear peptide of similar length, but the tryptophan and histidine residues remain sensitive to light and oxidation. Standard cold-chain practice therefore applies: keep the dry powder cold, dry and dark; let the vial reach room temperature before opening to avoid condensation; and use sterile technique.

• Adding diluent: run bacteriostatic water slowly down the inner wall of the vial rather than onto the cake. For cell-based work, use a preservative-free sterile diluent.
• Dissolving: swirl gently. The free carboxylate gives good aqueous solubility, so vigorous mixing is unnecessary; do not vortex or shake.
• After reconstitution: store cold and protected from light, label with concentration and date, and divide into single-use aliquots if the stock will be kept beyond a short working period.

The concentration is mass divided by volume. The table gives worked examples using a molecular weight of about 1,025 g/mol; note that actual peptide content is lower than gross vial mass when counter-ions and residual water are present, so a lot with a stated net peptide content should be calculated from that figure.

Use the reconstitution calculator for other vial sizes, the general procedure in how to reconstitute a lyophilized peptide, and the compound-specific page PT-141 reconstitution and storage. Broader cold-chain principles are in storing research peptides. Reconstitution cannot restore purity that was never present, so check the documentation for the lot before relying on a solution.

Purity, COA and quality

For a cyclic peptide, a certificate of analysis should do more than state a purity percentage. A usable document includes the HPLC chromatogram with method conditions and detection wavelength (typically 214-220 nm for the peptide bond), the mass-spectrometry result showing the observed mass against the theoretical value for the cyclic product, the lot number matching the vial, and the test date. Because the linear precursor is 18 Da heavier, the observed mass is what distinguishes closed from open ring, while retention time and peak shape help detect diastereomers and dimers that mass alone cannot separate. Ask whether the stated purity is by peak area at a single wavelength, and whether net peptide content has been reported.

The background is covered in how to read a COA and understanding HPLC purity. Current batch documents are on the COA page, and compound-specific discussion of identity verification is in PT-141 purity testing. For sourcing criteria see where to buy PT-141 for research.

Related compounds and comparisons

• KPV and alpha-MSH: a tripeptide fragment from the alpha-MSH C-terminus compared with the full hormone in KPV vs alpha-MSH.
• Peptide fundamentals: understanding amino acid sequences explains notation such as D-Phe and Nle used here.

A convenient way to place PT-141 within the family is to compare how each molecule differs structurally from the endogenous ligand.

Study design considerations

Experiments with PT-141 are most informative when a few controls are built in. Express receptors in a defined background and measure their expression rather than inferring it from the cell line name. Run a melanotan-II comparator side by side so that structural effects are not confused with assay drift. Include a time course, a vehicle that matches the diluent (including any preservative), and a selective antagonist to test receptor dependence. Report both binding and functional measures, and record lot number, net peptide content and storage history with every dataset. Findings should be described as receptor agonism in a defined experimental system, not as a general prediction for every biological setting.

Frequently asked questions

Is PT-141 the same as bremelanotide?

Yes. PT-141 and bremelanotide are two names for the same cyclic heptapeptide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Melanotan-II is a related but different peptide.

How does PT-141 differ structurally from melanotan-II?

They share the same lactam-bridged cyclic core, but PT-141 ends in a free carboxylic acid while melanotan-II ends in a primary amide. This formally deamidated terminus changes solubility slightly and shifts receptor emphasis in assays.

Which receptor does PT-141 mainly engage in research?

The principal focus is the melanocortin-4 receptor (MC4R), a Gs-coupled receptor found widely in the central nervous system. Activity at other melanocortin receptors depends on the assay system, so selectivity should be measured in receptor-defined cells rather than assumed.

What second messenger is measured in PT-141 assays?

Cyclic AMP is the standard functional readout because MC4R signals through Gs and adenylyl cyclase. Because cAMP alone cannot identify the receptor responsible, it is paired with binding and receptor-defined or knockout controls.

What is the molecular weight of PT-141?

About 1,025 g/mol, with formula C50H68N14O10. This value is used to convert mg/mL to molarity, though net peptide content from the certificate of analysis should be used if the lot reports it.

Why does ring closure matter for quality control?

The uncyclized linear precursor is about 18 Da heavier than the cyclic product, and incomplete cyclization is a recognized impurity. Mass spectrometry detects this difference, while HPLC retention behavior helps detect dimers and diastereomers that have nearly the same mass. See PT-141 purity testing.

How should lyophilized PT-141 be stored?

Cold, dry and protected from light until needed. The cyclic backbone helps resist exopeptidases, but tryptophan and histidine remain sensitive to light and oxidation. After reconstitution, keep it cold and dark and use single-use aliquots. See PT-141 reconstitution and storage.

How is a PT-141 stock concentration calculated?

Divide the peptide mass in the vial by the diluent volume: 10 mg in 2 mL gives 5 mg/mL, or about 4.9 mM. The calculator automates this for other vial sizes.

Can results from melanotan-II be applied to PT-141?

Not without direct comparison. The two peptides differ at the C-terminus and in receptor profile, and sequence termini, ring chemistry, purity and model context can all alter observed behavior. Parallel experiments are the appropriate way to compare them.

Where can I find the research-grade product and its documentation?

The PT-141 product page lists the material, and batch certificates of analysis are on the COA page. Sourcing criteria are discussed in where to buy PT-141 for research.

Research-use statement

PT-141 is supplied by V8 Peptides as a laboratory reagent. This guide summarizes published chemistry and preclinical pharmacology and is not guidance on use in people or animals. Verify each lot against its certificate of analysis and handle reconstituted material according to your institution's laboratory procedures. For laboratory research use only; not for human consumption.

Material specifications are on the PT-141 research vial product page.

References

1. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA. 1980;77(10):5754-5758.
2. Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. Design of a new class of superpotent cyclic alpha-melanotropins based on quenched dynamic simulations. J Am Chem Soc. 1989;111(9):3413-3416.
3. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
4. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci USA. 2004;101(27):10201-10204.
5. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736-749.
6. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930.